Page 3 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Activating construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Activating Construct Today - Breaking & Trending Today

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral . Seite 1 ....

United States , San Francisco , Himisha Beltran , Drug Administration , Md Dana Farber Cancer Institute , Harpoon Therapeutics Inc , Harpoon Therapeutics Abstract , Rapid Oral Presentation , Clinical Oncology Genitourinary Cancers Symposium , American Society , Activating Construct , T Cell Engager , Neuroendocrine Prostate Cancer , Neuroendocrine Neoplasms , Rapid Oral Abstract Session , Prostate Cancer , Dana Farber Cancer Institute , Orphan Drug Designation , Harpoon Therapeutics ,

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , Luke Walker , Sumit Madan , Banner Md Anderson Cancer Center , Ut Md Anderson Cancer Center , Harpoon Therapeutics Inc , American Society Of Hematology , Exchange Commission , American Society , Annual Meeting , Overall Response Rate , Very Good Partial Response , Cancer Center , Associate Professor , Chief Medical Officer , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , San Diego , Sumit Madan , Harpoon Therapeutics Inc , American Society Of Hematology , Banner Md Anderson Cancer Center , Exchange Commission , Therapeutics Abstract , American Society , Annual Meeting , Completed Dose Escalation Portion , Targetingb Cell Maturation Antigen , Refractory Multiple Myeloma , Prospective Therapeutics Trials , Refractory Myeloma , Manchester Grand Hyatt San Diego , Seaport Ballroom , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics Announces Up to $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a. ....

United States , Canaccord Genuity , Globenewswire Inc , Hc Wainwright Co , Harpoon Therapeutics Inc , Exchange Commission , Leaf Venture Partners , Cormorant Asset Management , Bridge Group , Point Capital , Securities Act , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act ,

Harpoon Therapeutics Announces Updated Interim Tolerability

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete. ....

Noura Choudhury , Luke Walker , Memorial Sloan Kettering Cancer Center , Exchange Commission , European Society Of Medical Oncology Congress , Harpoon Therapeutics Inc , Drug Administration , European Society , Medical Oncology Congress , Activating Construct , Principal Investigator , Chief Medical Officer , Orphan Drug Designation , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic , Nasdaq Harp , Harpoon Therapeutics Inc ,